Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior

European Journal of Pharmaceutical Sciences

Volumn 32, Issue 3, 2007, Pages 200-208

  Geldof, Marian ^d   Freijer, Jan ^d   van Beijsterveldt, Ludy ^c   Vermote, Patrick C M ^c   Megens, Anton A ^c   Danhof, Meindert ^a,b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LAP and P Consultants BV   (Netherlands)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d NONE

Author keywords

Excitation; Flat body posture; Forepaw trampling; Pharmacokinetics; Proportional odds model; Selective serotonin reuptake inhibitor

Indexed keywords

CHLORAMPHETAMINE; FLUVOXAMINE MALEATE; SEROTONIN UPTAKE INHIBITOR;

ACCURACY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY POSTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; EXCITATION; FLAT BODY POSTURE; FOREPAW TRAMPLING; MALE; NONHUMAN; PARAMETER; PHARMACODYNAMICS; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL ODDS MODEL; RAT; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TAIL; WISTAR RAT;

ANIMALS; BEHAVIOR, ANIMAL; FEASIBILITY STUDIES; FLUVOXAMINE; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; P-CHLOROAMPHETAMINE; RATS; RATS, WISTAR; SEROTONIN AGENTS; SEROTONIN UPTAKE INHIBITORS;

EID: 34948845565     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2007.07.004     Document Type: Article

References (43)

1. Agresti A. Modelling ordered categorical data: recent advances and future challenges. Stat. Med. 18 (1999) 2191-2207
2. Andres J.I., Alcazar J., Alonso J.M., Alvarez R.M., Bakker M.H., Biesmans I., Cid J.M., De Lucas A.I., Fernandez J., Font L.M., Hens K.A., Iturrino L., Lenaerts I., Martinez S., Megens A.A., Pastor J., Vermote P.C., and Steckler T. Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity. J. Med. Chem. 48 (2005) 2054-2071
3. Andres J.I., Alcazar J., Alonso J.M., Alvarez R.M., Cid J.M., De Lucas A.I., Fernandez J., Martinez S., Nieto C., Pastor J., Bakker M.H., Biesmans I., Heylen L.I., and Megens A.A. Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and alpha(2)-adrenoceptor antagonistic activities: a novel series of potential antidepressants. Bioorg. Med. Chem. Lett. 13 (2003) 2719-2725
4. Bartolome J.M., Alcudia A., Andres J.I., Cid J.M., Garcia M., Megens A., Toledo M.A., and Trabanco A.A. Novel 2-N,N-dimethylaminomethyl-2,3,3a,12b-tetrahydrodibenzo[b,f]furo[2,3-d]oxep in derivatives displaying combined norepinephrine reuptake inhibition and 5-HT2A/2C receptor antagonism. Bioorg. Med. Chem. Lett. 15 (2005) 2898-2901
5. Berger U.V., Grzanna R., and Molliver M.E. Depletion of serotonin using p-chlorophenylalanine (PCPA) and reserpine protects against the neurotoxic effects of p-chloroamphetamine (PCA) in the brain. Exp. Neurol. 103 (1989) 111-115
6. Bouillon T., Meineke I., Port R., Hildebrandt R., Gunther K., and Gundert-Remy U. Concentration-effect relationship of the positive chronotropic and hypokalaemic effects of fenoterol in healthy women of childbearing age. Eur. J. Clin. Pharmacol. 51 (1996) 153-160
7. Danhof M., Alvan G., Dahl S.G., Kuhlmann J., and Paintaud G. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm. Res. 22 (2005) 1432-1437
8. Danhof M., Van der Graaf P.H., Jonker D.M., Visser S.A.G., and Zuideveld K.P. Mechanism-based pharmacokinetic-pharmacodynamic modeling for prediction of in vivo drug concentration-effect relationships-application in drug candidate selection and lead optimization. In: Taylor J.B., and Triggle D.J. (Eds). Comprehensive Medicinal Chemistry II (2007), Elsevier, Amsterdam pp. 885-908
9. Danhof M., De Jongh J., De Lange E.C.M., Della Pasqua O., Ploeger B.A., and Voskuyl R.A. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory and dynamical systems analysis. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 357-400
10. Della Paschoa O.E., Kruk M.R., and Danhof M. Phamacokinetic-pharmacodynamic modelling of behavioural responses. Neurosci. Biobehav. Rev. 23 (1998) 229-236
11. Fuller R.W. Mechanism by which uptake inhibitors antagonize p-chloroamphetamine-induced depletion of brain serotonin. Neurochem. Res. 5 (1980) 241-245
12. Fuller R.W. Effects of p-chloroamphetamine on brain serotonin neurons. Neurochem. Res. 17 (1992) 449-456
13. Geldof M., Freijer J., Van Beijsterveldt L., Timmerman P., Ahnaou A., Drinkenburg W.I.H.M., and Danhof M. Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behvioral studies. Eur. J. Pharm. Sci 30 (2007) 45-55
14. Goodnick P.J., and Goldstein B.J. Selective serotonin reuptake inhibitors in affective disorders. I. Basic pharmacology. J. Psychopharmacol. 12 (1998) S5-S20
15. Harrell Jr. F.E., Lee K.L., and Pollock B.G. Regression models in clinical studies: determining relationships between predictors and response. J. Natl. Cancer Inst. 80 (1988) 1198-1202
16. Hashimoto Y., and Sheiner L.B. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis. J. Pharmacokinet. Biopharm. 19 (1991) 333-353
17. Hutson P.H., and Curzon G. Concurrent determination of effects of p-chloroamphetamine on central extracellular 5-hydroxytryptamine concentration and behaviour. Br. J. Pharmacol. 96 (1989) 801-806
18. Jonker D.M., Van de Mheen C., Eilers P.H.C., Kruk M.R., Voskuyl R.A., and Danhof M. Anticonvulsant drugs differentially suppress individual ictal signs: a pharmacokinetic-pharmacodynamic analysis in the cortical stimulation model in the rat. Behavior. Neurosci. 117 (2003) 1076-1085
19. Jonker D.M., Visser S.A., Van der Graaf P.H., Voskuyl R.A., and Danhof M. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol. Ther. 106 (2005) 1-18
20. Karlsson M.O., Port R.E., Ratain M.J., and Sheiner L.B. A population model for the leukopenic effect of etoposide. Clin. Pharmacol. Ther. 57 (1995) 325-334
21. Kelliher P., Kelly J.P., Leonard B.E., and Sanchez C. Effects of acute and chronic administration of selective monoamine re-uptake inhibitors in the rat forced swim test. Psychoneuroendocrinology 28 (2003) 332-347
22. Knibbe C.A., Zuideveld K.P., DeJongh J., Kuks P.F., Aarts L.P., and Danhof M. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. Clin. Pharmacol. Ther. 72 (2002) 670-684
23. Lassen J.B. Influence of the new 5-HT-uptake inhibitor paroxetine on hypermotility in rats produced by p-chloroamphetamine (PCA) and 4,alpha-dimethyl-7-tyramine (H 77/77). Psychopharmacology (Berlin) 57 (1978) 151-153
24. Mandema J.W., Kuck M.T., and Danhof M. In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy. J. Pharmacol. Exp. Ther. 261 (1992) 56-61
25. Mandema J.W., and Stanski D.R. Population pharmacodynamic model for ketorolac analgesia. Clin. Pharmacol. Ther. 60 (1996) 619-635
26. Mandema J.W., Tukker E., and Danhof M. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. J. Pharmacol. Exp. Ther. 260 (1992) 36-44
27. Minto C.F., Howe C., Wishart S., Conway A.J., and Handelsman D.J. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J. Pharmacol. Exp. Ther. 281 (1997) 93-102
28. Minto C.F., Schnider T.W., Egan T.D., Youngs E., Lemmens H.J., Gambus P.L., Billard V., Hoke J.F., Moore K.H., Hermann D.J., Muir K.T., Mandema J.W., and Shafer S.L. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 86 (1997) 10-23
29. Nestorov I., Graham G., Duffull S., Aarons L., Fuseau E., and Coates P. Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan. Pharm. Res. 18 (2001) 1210-1219
30. Olofsen E., Romberg R., Bijl H., Mooren R., Engbers F., Kest B., and Dahan A. Alfentanil and placebo analgesia: no sex differences detected in models of experimental pain. Anesthesiology 103 (2005) 130-139
31. Pellegrino T.C., and Bayer B.M. Specific serotonin reuptake inhibitor-induced decreases in lymphocyte activity require endogenous serotonin release. Neuroimmunomodulation 8 (2000) 179-187
32. Rosario M.C., Jacqmin P., Dorr P., van der R.E., and Hitchcock C. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc. Clin. Pharmacol. Ther. 78 (2005) 508-519
33. Schnider T.W., Minto C.F., Bruckert H., and Mandema J.W. Population pharmacodynamic modeling and covariate detection for central neural blockade. Anesthesiology 85 (1996) 502-512
34. Schoemaker R.C., and Cohen A.F. Estimating impossible curves using NONMEM. Br. J. Clin. Pharmacol. 42 (1996) 283-290
35. Sheiner L.B. A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clin. Pharmacol. Ther. 56 (1994) 309-322
36. Sheiner L.B., and Ludden T.M. Population pharmacokinetics/dynamics. Annu. Rev. Pharmacol. Toxicol. 32 (1992) 185-209
37. Takamori K., Yoshida S., and Okuyama S. Availability of learned helplessness test as a model of depression compared to a forced swimming test in rats. Pharmacology 63 (2001) 147-153
38. Teste J.F., Pelsy-Johann I., Decelle T., and Boulu R.G. Anti-immobility activity of different antidepressant drugs using the tail suspension test in normal or reserpinized mice. Fundam. Clin. Pharmacol. 7 (1993) 219-226
39. Trulson M.E., and Jacobs B.L. Behavioral evidence for the rapid release of CNS serotonin by PCA and fenfluramine. Eur. J. Pharmacol. 36 (1976) 149-154
40. Vis P., Della P.O., Kruk M., Martin D., Mocaer E., Danhof M., and Jochemsen R. Population pharmacokinetic-pharmacodynamic modelling of S 15535, a 5-HT(1A) receptor agonist, using a behavioural model in rats. Eur. J. Pharmacol. 414 (2001) 233-243
41. Vozeh S., Steimer J.L., Rowland M., Morselli P., Mentre F., Balant L.P., and Aarons L. The use of population pharmacokinetics in drug development. Clin. Pharmacokinet. 30 (1996) 81-93
42. Yuh L., Beal S., Davidian M., Harrison F., Hester A., Kowalski K., Vonesh E., and Wolfinger R. Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography. Biometrics 50 (1994) 566-575
43. Zuideveld K.P., Treijtel N., Maas H.J., Gubbens-Stibbe J.M., Peletier L.A., Der Graaf P.H., and Danhof M. A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia. J. Pharmacol. Exp. Ther. 300 (2002) 330-338